Literature DB >> 7400825

Controversies about the treatment of myasthenia gravis.

L P Rowland.   

Abstract

Clinicians treating patients with myasthenia gravis must choose cholinergic drugs, corticosteroids, immunosuppressive drugs, thymectomy, or plasmapheresis. Clinicians must decide the sequence or combination of these therapies and when to deem lack of improvement a sign for a different therapeutic approach. Because controlled trials have not been done to evaluate therapies that may require months or years before benefit is evident, controversy abounds.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7400825      PMCID: PMC490631          DOI: 10.1136/jnnp.43.7.644

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  113 in total

1.  Evaluation of medical practices. The case for technology assessment.

Authors:  H V Fineberg; H H Hiatt
Journal:  N Engl J Med       Date:  1979-11-15       Impact factor: 91.245

2.  Studies in myasthenia gravis: early thymectomy. Electrophysiologic and pathologic correlations.

Authors:  G Genkins; A E Papatestas; S H Horowitz; P Kornfield
Journal:  Am J Med       Date:  1975-04       Impact factor: 4.965

3.  Investigations into thymic disease and tumour formation.

Authors:  G KEYNES
Journal:  Br J Surg       Date:  1955-03       Impact factor: 6.939

4.  Thymectomy for myasthenia gravis.

Authors:  A Farnsworth; W Pories; H Mendelsohn
Journal:  Aust N Z J Surg       Date:  1976-05

5.  The place of surgery in the treatment of myasthenia gravis.

Authors:  K Fraser; J A Simpson; J Crawford
Journal:  Br J Surg       Date:  1978-05       Impact factor: 6.939

6.  Myasthenia gravis and invasive thymoma: a 20-year experience.

Authors:  A J Goldman; C Herrmann; J C Keesey; D G Mulder; W J Brown
Journal:  Neurology       Date:  1975-11       Impact factor: 9.910

7.  Neostigmine methylsulfate. Does it have a chronic effect as well as a transient one?

Authors:  M D Ward; M S Forbes; T R Johns
Journal:  Arch Neurol       Date:  1975-12

8.  Plasma pyridostigmine levels in patients with myasthenia gravis.

Authors:  T N Calvey; K Chan
Journal:  Clin Pharmacol Ther       Date:  1977-02       Impact factor: 6.875

9.  Symposium on therapeutic controversies. Myasthenia gravis. Plasmapheresis in the treatment of myasthenia gravis.

Authors:  R P Lisak; D L Schotland
Journal:  Trans Am Neurol Assoc       Date:  1978

10.  Effect of corticosteroids on sciatic nerve-tibialis anterior muscle of rats treated with hemicholinium-3. An experimental approach to a possible mechanism of action of corticosteroids in myasthenia gravis.

Authors:  R S Leeuwin; E C Wolters
Journal:  Neurology       Date:  1977-02       Impact factor: 9.910

View more
  27 in total

1.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

Review 2.  Thymectomy for myasthenia gravis.

Authors:  J D Urschel; R P Grewal
Journal:  Postgrad Med J       Date:  1998-03       Impact factor: 2.401

Review 3.  The natural course of myasthenia gravis.

Authors:  V Fonseca; C W Havard
Journal:  BMJ       Date:  1990-06-02

4.  Long term treatment of myasthenia gravis with azathioprine.

Authors:  V Fonseca; C W Havard
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

5.  Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis.

Authors:  R Mantegazza; C Antozzi; D Peluchetti; A Sghirlanzoni; F Cornelio
Journal:  J Neurol       Date:  1988-11       Impact factor: 4.849

Review 6.  Intravenous immune globulin in myasthenia gravis.

Authors:  P Gajdos
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 7.  History of Myasthenia Gravis Revisited.

Authors:  Feza Deymeer
Journal:  Noro Psikiyatr Ars       Date:  2020-11-07       Impact factor: 1.339

8.  A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis.

Authors:  C W Olanow; A S Wechsler; A D Roses
Journal:  Ann Surg       Date:  1982-08       Impact factor: 12.969

9.  A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

10.  Myasthenia gravis. Pathogenesis and current concepts in management.

Authors:  C W Havard; G K Scadding
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.